AbbVie, a biotech company that develops and commercializes medicines, announced today that it will acquire Nimble Therapeutics.

According to a release, the proposed acquisition adds Nimble’s lead asset, which is an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis. The acquisition also will allow AbbVie to use Nimble’s proprietary peptide synthesis platform to enable the discovery and optimization of oral peptide therapeutics.

“With AbbVie’s world-class expertise in developing and commercializing medicines on a global scale, Nimble’s novel oral therapies will be well-positioned to reach more people living with autoimmune diseases,” Nimble Therapeutics Founder and Chief Executive Officer Jigar Patel, Ph.D., said in a statement. “The talented, passionate and dedicated team at Nimble has made great progress over the past few years, and we are pleased that AbbVie has recognized the tremendous potential of our proprietary platform and emerging immunology pipeline.”

AbbVie will make a cash payment of $200 million at closing to acquire Nimble.